Top 11 CRISPR Stocks To Invest In

In this article, we discuss the top 11 CRISPR stocks to invest in.

Genome editing refers to a set of technologies enabling scientists to modify an organism’s DNA by adding, removing, or altering genetic material at specific locations in the genome, as defined by MedlinePlus. One prominent method is CRISPR-Cas9, derived from bacteria’s natural immune defense system against viruses. In this system, bacteria create CRISPR arrays by incorporating small pieces of viral DNA. If the viruses return, the bacteria use RNA segments from the CRISPR arrays to recognize and bind to specific regions of the viral DNA. The enzyme Cas9 then cuts the DNA, disabling the virus. CRISPR-Cas9 stands out for its speed, cost-effectiveness, accuracy, and efficiency compared to other genome editing methods.

CRISPR has broad medical applications. For example, Swedish researchers utilized CRISPR-Cas9 to edit the rs10071329 genetic variant in human brown adipocytes, transforming it from A/A to G/G. This alteration increased PPARGC1B levels, resulting in elevated triglyceride accumulation, enhanced mitochondrial gene expression, improved mitochondrial respiration, and a heightened lipolysis response to norepinephrine. These findings suggest the potential of PPARGC1B genetic variants as therapeutic targets for precision medicine in obesity. Meanwhile, Chinese researchers demonstrated prime editing using CRISPR-Cas12a and circular RNAs in human cells. They developed circular RNA-mediated prime editor (CPE) systems targeting T-rich areas, enabling potential multiplex editing with efficiencies reaching up to 40.75% in human cells.

The valuation of the global CRISPR Cas9 market was $2480.95 million in 2022, and it is anticipated to increase at a compound annual growth rate (CAGR) of 34.05% through the forecast period, reaching $14395.61 million by 2028. Cell and gene therapies show potential for treating or curing certain cancers and rare diseases, though they are among the most expensive treatments globally, with some costing between $400,000 and $2 million per dose. Despite the high costs, the Cell and gene therapies market is anticipated to nearly quadruple over the next three years, increasing from $5.3 billion in 2022 to an estimated $19.9 billion by 2027.

2023 marked a significant breakthrough for cell and gene therapies, with seven FDA approvals in the US and one in the European Union. The global landscape includes over 2,000 ongoing clinical trials, with approximately 10% in Phase III, suggesting that around 75 therapies could be approved well before 2030. Projections for 2024 estimate approximately 17 approvals in the US and EU combined. Presently, there are 33 approved cell and gene therapy products listed on the FDA’s website, with seven of them gaining approval in 2023. These include treatments for sickle cell disease, Duchenne muscular dystrophy, wounds in dystrophic epidermolysis bullosa (DEB) patients, severe hemophilia A, neutrophil recovery, and type 1 diabetes using innovative cellular and gene-based approaches. In 2024, experts expect the initial approval of adoptive cell therapy for solid tumors and the first approval of an allogeneic T-cell therapy in the United States.

To benefit from the growth potential in the gene editing market, some of the stocks to invest in include Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), and Exact Sciences Corporation (NASDAQ:EXAS). 

Our Methodology 

We chose the top gene editing stocks based on overall hedge fund sentiment toward each stock. We have assessed the hedge fund sentiment from Insider Monkey’s database of 910 elite hedge funds tracked as of the end of the third quarter of 2023. The list is arranged in ascending order of the number of hedge fund holders in each firm. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here). 

A woman in a lab coat examining a syringe of gene editing medicine in a laboratory setting.

Top CRISPR Stocks To Invest In

11. Beam Therapeutics Inc. (NASDAQ:BEAM)

Number of Hedge Fund Holders: 17

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. On January 29, JP Morgan raised its rating on Beam Therapeutics Inc. (NASDAQ:BEAM) to Overweight, attributing the upgrade to the promising outlook for its BEAM-302 treatment for alpha-1 antitrypsin deficiency (AATD). The investment bank anticipates AATD to become a significant focus in therapeutics in 2024, with BEAM-302 considered a standout gene therapy candidate, demonstrating exceptional disease-modifying potential for a broad range of patients. According to JP Morgan, AATD represents a commercial opportunity estimated at around $12 billion.

According to Insider Monkey’s third quarter database, 17 hedge funds were bullish on Beam Therapeutics Inc. (NASDAQ:BEAM), compared to 20 funds in the prior quarter. Cathie Wood’s ARK Investment Management is the largest stakeholder of the company, with 8.7 million shares worth $211.25 million. 

Like Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), and Exact Sciences Corporation (NASDAQ:EXAS), Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best CRISPR stocks to buy. 

Here is what Baron Health Care Fund has to say about Beam Therapeutics Inc. (NASDAQ:BEAM) in their Q1 2021 investor letter:

“Beam Therapeutics Inc. is a biotechnology company pioneering a novel technology called base editing, which allows for individual base pairs (the letters of DNA) to be modified. Shares fell along with other biotechnology stocks driven by a sudden rise in treasury yields. Early stage biotechnology stocks are particularly sensitive to interest rates because their cash flows are further in the future. We believe we are entering into a phase of significant advancement for the gene editing field that will eventually lead to curative therapies, and we think Beam has a unique platform technology.”

10. Editas Medicine, Inc. (NASDAQ:EDIT)

Number of Hedge Fund Holders: 21

Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage genome editing company, with a focus on developing transformative genomic medicines for various serious diseases. Utilizing its proprietary CRISPR-based gene editing platform, the company is advancing EDIT-101 in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10 and autosomal dominant retinitis pigmentosa. It is one of the best gene editing stocks to invest in. 

On December 13, Editas Medicine, Inc. (NASDAQ:EDIT) announced a licensing agreement with Vertex Pharmaceuticals. The agreement grants Vertex a non-exclusive license for Editas Medicine, Inc. (NASDAQ:EDIT)’s Cas9 gene editing technology, specifically targeting certain blood disorders such as sickle cell disease and beta-thalassemia. This technology is used in the development of ex vivo gene editing medicines, including the recently approved Casgevy therapy. As a result of this deal, Editas expects to extend its cash runway into 2026.

According to Insider Monkey’s third quarter database, 21 hedge funds were bullish on Editas Medicine, Inc. (NASDAQ:EDIT), compared to 26 funds in the prior quarter. 

9. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 24

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing company that uses its CRISPR/Cas9 platform to develop gene-based medicines. The company’s technology enables precise changes to genomic DNA. CRISPR Therapeutics AG (NASDAQ:CRSP) has a diverse therapeutic program portfolio, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. It is one of the best gene editing stocks to invest in. 

On November 6, CRISPR Therapeutics AG (NASDAQ:CRSP) reported a Q3 GAAP EPS of -$1.41, beating market estimates by $0.57. As of September 30, 2023, cash, cash equivalents, and marketable securities amounted to $1,739.8 million, reflecting a decrease of $128.6 million from the $1,868.4 million reported on December 31, 2022. The decline was primarily attributed to operating expenses but partially offset by payments received from Vertex, associated with a non-exclusive license agreement, along with interest income.

According to Insider Monkey’s third quarter database, Cathie Wood’s ARK Investment Management is the leading stakeholder of the company, with 7.16 million shares worth over $325 million. 

8. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 27

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a genome editing company focused on developing curative therapeutics. Established in 2014, the company is dedicated to developing novel genomic medicines using CRISPR/Cas9 technology. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene editing stocks to invest in. 

On November 14, Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced that its drug candidate NTLA-2002, designed for the treatment of hereditary angioedema, has been granted orphan drug designation by the EU. NTLA-2002 is an investigational therapy utilizing in-vivo CRISPR technology, targeting the reduction of swelling attacks in individuals with hereditary angioedema.

According to Insider Monkey’s third quarter database, 27 hedge funds were bullish on Intellia Therapeutics, Inc. (NASDAQ:NTLA), compared to 29 funds in the preceding quarter. David Kroin’s Deep Track Capital is a prominent stakeholder of the company, with a position worth $63.2 million.

Carillon Tower Advisers discussed its stance on Intellia Therapeutics, Inc. (NASDAQ:NTLA) in its Q2 2021 investor letter:

“Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”

7. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Number of Hedge Fund Holders: 31

Pacific Biosciences of California, Inc. (NASDAQ:PACB) specializes in designing, developing, and manufacturing sequencing systems to address genetically complex issues. Their products include sequencing systems, consumables like single molecule real-time (SMRT) cells, and reagent kits for specific workflows. It is one of the best gene editing stocks to buy. 

Pacific Biosciences of California, Inc. (NASDAQ:PACB) has created an enrichment method for focused SMRT Sequencing on the PacBio Sequel System, utilizing the CRISPR-Cas9 system, eliminating the need for PCR amplification. This approach, combined with the long reads, high consensus accuracy, and even coverage of SMRT Sequencing, enables the sequencing of genomic regions, including those with difficult sequence contexts that are not accessible with alternative technologies.

According to Insider Monkey’s third quarter database, Thomas Steyer’s Farallon Capital is a prominent stakeholder of the company, with 10.2 million shares worth $85.3 million. Overall, 31 hedge funds were bullish on Pacific Biosciences of California, Inc. (NASDAQ:PACB). 

Jackson Square Partners made the following comment about Pacific Biosciences of California, Inc. (NASDAQ:PACB) in its Q3 2022 investor letter:

“Pacific Biosciences of California, Inc. (NASDAQ:PACB): emerging player in genomic sequencing with its highly differentiated long-read technology; poised to unlock a multi-year share shift towards long-read sequencing as new products dramatically improve throughput and cost to competitively advantaged levels.”

6. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 37

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company that focuses on discovering, developing, and commercializing messenger RNA (mRNA) therapeutics and vaccines. On February 22, 2023, Moderna, Inc. (NASDAQ:MRNA) announced that it is venturing into gene editing by partnering with Life Edit Therapeutics, a subsidiary of ElevateBio. The collaboration aims to develop potentially permanent treatments for rare genetic diseases utilizing CRISPR technologies. Moderna, Inc. (NASDAQ:MRNA) will fund preclinical research studies, leveraging Life Edit’s precise gene-editing tools, which are based on CRISPR technology. This initiative seeks to establish a gene editing franchise, utilizing technologies similar to those employed in Moderna’s COVID-19 vaccines.

According to Insider Monkey’s third quarter database, 37 hedge funds were long Moderna, Inc. (NASDAQ:MRNA), compared to 40 funds in the prior quarter. ARK Investment Management is the largest stakeholder of the company, with 29.8 million shares worth $249 million. 

Like Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), and Exact Sciences Corporation (NASDAQ:EXAS), Moderna, Inc. (NASDAQ:MRNA) is one of the best gene editing stocks. It is ranked 6th on our list. 

Baron Health Care Fund made the following comment about Moderna, Inc. (NASDAQ:MRNA) in its Q1 2023 investor letter:

“Moderna, Inc. (NASDAQ:MRNA) is a leader in the emerging field of mRNA-based vaccines and therapeutics and was one of the three main producers of the COVID vaccine. Shares fell during the quarter. We believe as COVID shifts away from pandemic status and becomes an increasingly commercial market (rather than government funded), there is increasing investor uncertainty around what a booster market could look like, which is pressuring shares. Looking beyond COVID, we think Moderna has the potential to disrupt the biopharmaceutical industry, from infectious disease vaccines to oncology, and we remain shareholders.”

5. Exact Sciences Corporation (NASDAQ:EXAS)

Number of Hedge Fund Holders: 45

Exact Sciences Corporation (NASDAQ:EXAS) specializes in cancer screening and diagnostic test products, operating both in the United States and internationally. Their flagship product is Cologuard, a non-invasive stool-based DNA screening test designed to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It is one of the best gene editing stocks to invest in. 

On January 2, Benchmark upgraded Exact Sciences Corporation (NASDAQ:EXAS) stock to Buy and included it among its “best ideas” for 2024. The investment firm anticipates that Exact Sciences Corporation (NASDAQ:EXAS) will benefit from consistent growth in its core business, ongoing advancements in the new product pipeline, and a favorable interest rate environment. 

According to Insider Monkey’s third quarter database, 45 hedge funds were long Exact Sciences Corporation (NASDAQ:EXAS), same as the prior quarter. Ken Griffin’s Citadel Investment Group is a prominent stakeholder of the company, with 1.7 million shares worth $115.7 million. 

Artisan Small Cap Fund made the following comment about Exact Sciences Corporation (NASDAQ:EXAS) in its Q3 2023 investor letter:

“Among our top detractors were Lattice Semiconductor, Shockwave and Exact Sciences Corporation (NASDAQ:EXAS). Exact Sciences is a leading provider of diagnostic testing and maker of the noninvasive colorectal cancer screening test Cologuard®. The stock was a top performer through the first half of the year but pulled back in Q3. The company reported strong financial results as 31% growth in screening revenues (mostly Cologuard®) drove an overall 19% revenue increase. However, screening revenues fell slightly short of elevated expectations and were not good enough to support the stock’s year-to-date outperformance. We continue to be bullish on Cologuard’s® long-term growth potential; the addressable market expanded significantly in 2021 when the United States Preventive Services Task Force lowered the recommended age for colorectal cancer screenings to 45 from 50. Our research indicates the lowered screening age expands the company’s addressable market by ~18 million unscreened individuals. We also believe meaningful long term opportunities exist as the company develops additional high-value cancer tests.”

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 50

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of medicines for eye disorders, allergies, inflammatory diseases, cardiovascular issues, infectious diseases, and rare diseases. It is one of the top gene editing stocks to invest in. 

On October 3, 2023, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia announced an extended research partnership aimed at developing CRISPR-based therapies for treating neurological and muscular diseases. The collaboration leverages Intellia’s advanced genome editing platform, including its exclusive Nme2Cas9 technology, in conjunction with Regeneron’s proprietary antibody-targeted viral vector delivery technologies. Together, the two companies aim to advance in vivo programs targeting neurological and muscular diseases beyond the liver.

According to Insider Monkey’s third quarter database, 50 hedge funds were bullish on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), compared to 56 funds in the prior quarter. D E Shaw is the leading stakeholder of the company, with 370,421 shares worth $304.8 million. 

Bronte Capital Amalthea Fund made the following comment about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2023 investor letter:

“In the last quarterly letter, we discussed the problems in our long book. These were:

1. a) companies that sell technical products to improve the conversion of grain into meat (such as animal genetics and feed additives), and
2. b) Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), which had received a “Complete Response Letter” (an FDA rejection) for their new longer-lasting wet age-related macular degeneration drug.

The first of these problems has persisted. Grain prices remain high relative to meat prices and the stocks in question have followed their quality European peers down. The two losers in this sector are Genus and DSM-Firmenich…” (Click here to read the full text)

3. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 55

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to address unmet medical needs globally. The company’s product portfolio includes treatments for HIV/AIDS, viral hepatitis, oncology, pulmonary arterial hypertension, and serious invasive fungal infections. It is one of the best gene editing stocks to invest in.

On August 17, 2020, Gilead Sciences, Inc. (NASDAQ:GILD) and Tango Therapeutics announced an expanded strategic collaboration, focusing on discovering, developing, and commercializing targeted immune evasion therapies for cancer patients. Building on their 2018 agreement, Tango will utilize its CRISPR-enabled functional genomics platform to identify novel immune evasion targets, increasing the number from five to 15. Gilead will have options for worldwide rights to programs targeting these newly identified targets over the next seven years. 

According to Insider Monkey’s third quarter database, 55 hedge funds were long Gilead Sciences, Inc. (NASDAQ:GILD), compared to 56 funds in the earlier quarter. Cliff Asness’ AQR Capital Management is the largest stakeholder of the company, with 4.7 million shares worth $357.7 million. 

In its fourth quarter 2023 investor letter, ClearBridge Dividend Strategy stated the following regarding Gilead Sciences, Inc. (NASDAQ:GILD):

“In the second half of 2023 — as we were selling low-growth, high-multiple stocks and taking advantage of oversold conditions in infrastructure, real estate and utilities — we also found opportunities in overlooked areas of health care. After adding Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, we bought AstraZeneca in the fourth quarter. Each of these stocks present distinct investment cases, but both are reasonably valued and have limited patent expiry or pipeline risk. Gilead’s strength comes from its dominant franchise in HIV. It offers lower growth, but it yields nearly 4% and trades at 11x earnings. AstraZeneca possesses a diversified portfolio of pharmaceuticals, which should deliver double-digit earnings growth, yet it trades at just 16x earnings. These stocks were underwritten individually, but collectively we like the idea of increasing our exposure to defensive and growing health care names at below-market multiples.”

2. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Holders: 57

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focused on developing and commercializing therapies for cystic fibrosis. It is one of the best gene editing stocks to buy. On January 16, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that it recently received FDA approval for its groundbreaking gene editing therapy, Casgevy, developed in collaboration with CRISPR Therapeutics. The approval is for individuals aged 12 years and older with transfusion-dependent beta-thalassemia (TDT). This follows the earlier FDA clearance for Casgevy in sickle cell disease, marking it as the first gene editing therapy to be approved in the U.S. Vertex also announced that nine clinical centers in the U.S. are now authorized to provide Casgevy for TDT patients, with additional sites scheduled to be launched in the coming weeks. 

According to Insider Monkey’s third quarter database, 57 hedge funds were bullish on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), compared to 54 funds in the last quarter. Ian Simm’s Impax Asset Management is the largest stakeholder of the company, with 558,138 shares worth $193.7 million. 

Global Equity Strategy stated the following regarding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its fourth quarter 2023 investor letter:

“Health Care outperformed due to a strong showing by US-based Vertex Pharmaceuticals, even as other holdings in the sector posted weak returns. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported positive phase 2 trial data for a drug to address diabetic neuropathic pain.

The potential for technological innovation to create shareholder value goes far beyond the effects of Al, of course. For example, Vertex Pharmaceuticals is building a significant competitive advantage through its unique approach to drug discovery.

Unlike most drug developers, which focus on mitigating symptoms of an illness, Vertex seeks to understand and address the causal biology of a disease more fully. This approach has helped the company establish a wide lead in treating cystic fibrosis (CF), a rare disease that causes mucus buildup in organs such as the lungs. Vertex’s research and treatments have targeted the root cause of CF, which is that a particular protein becomes misfolded and unable to move chloride out of a cell, resulting in an imbalance between salt and water. Its scientists have been able to do this by working with the lung cells of real CF patients, an advantage over using engineered animal cells to simulate the disease-causing mechanism to determine which drug candidate is most promising for humans. Vertex’s latest therapy, approved in 2019, is Trikafta, a combination of three medicines that targets a mutation found in 90% of CF patients. Vertex is now using the same approach to address other illnesses. In 2023, Casgevy, its treatment for sickle cell disease, became the first CRISPR-based gene-editing therapy to receive regulatory approval. (CRISPR, a technology honored by the Nobel Prize in 2020, allows scientists to make precise changes to parts of the genome, the set of DNA instructions found in a cell.) By correcting the faulty gene that causes sickle cell disease, Casgevy could offer a one-time therapy to cure approximately 16,000 patients who have the red blood cell disorder-a significant improvement over the usual course of treatment, which is merely to manage symptoms through blood transfusions and pain medicines…” (Click here to read the full text)

1. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 73

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company engaged in discovering, developing, manufacturing, and selling medicines and vaccines worldwide. The company’s portfolio includes products in therapeutic areas such as cardiovascular, metabolic, infectious diseases, women’s health, and COVID-19 prevention and treatment. It is one of the best gene editing stocks to monitor. 

On July 6, 2023, Pfizer Inc. (NYSE:PFE) invested $25 million in Caribou Biosciences, expressing confidence in the gene-editing company and providing additional funding for its experimental multiple myeloma treatment, CB-011. The investment is earmarked for advancing CB-011, currently in Phase 1 testing for relapsed or refractory multiple myeloma patients. In return, Pfizer Inc. (NYSE:PFE) obtains a right of first negotiation if Caribou explores discussions with potential partners for CB-011. This investment not only boosts investor sentiment but also brings Pfizer’s developmental expertise to support Caribou’s efforts.

According to Insider Monkey’s third quarter database, 73 hedge funds were bullish on Pfizer Inc. (NYSE:PFE), same as the prior quarter. D E Shaw is the leading stakeholder of the company, with 13.15 million shares worth $436.2 million. 

Smead Value Fund made the following comment about Pfizer Inc. (NYSE:PFE) in its Q3 2023 investor letter:

“Through the first nine months of the year, we had a gain of 2.10%. The S&P 500 had a gain of 13.07% and the Russell 1000 Value had a gain of 1.79%. The stock market realized markedly higher riskless US Treasury interest rates had their effect on the stock market as it began to reassert what Warren Buffett calls the “gravitational pull” on price-to-earnings ratios (P/E).

On the downside, Target (TGT), Bank of America (BAC) and Pfizer Inc. (NYSE:PFE) detracted the most in the first nine months of the year. Pfizer (PFE) is suffering from a fall-off in Covid-19 vaccinations and we are trying to figure out what to do with it as a small holding.”

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out 13 Best Big Company Stocks to Buy and 12 Highest-Paid Women CEOs. 

Suggested articles:

• Top 12 Oil and Gas Stocks To Invest In According To Hedge Funds
• 10 Best Fintech Stocks To Buy In 2024
• 11 Best FAANG Stocks To Invest In

Disclosure: None. Top 11 CRISPR Stocks To Invest In is originally published on Insider Monkey.